
Opinion|Videos|April 16, 2025
Key Learnings From the CATALYST Study on Hypercortisolism Prevalence
Experts discuss the challenges of identifying and diagnosing hypercortisolism, the reasons behind its often-delayed diagnosis, the impact of a wide spectrum of clinical signs and symptoms on clinicians’ ability to diagnose the condition, and recent data on the prevalence of hypercortisolism in at-risk populations, including those with difficult-to-control diabetes, hypertension, and cardiovascular disease.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are some of the challenges of identifying and diagnosing hypercortisolism?
- The diagnosis of hypercortisolism is often delayed by several years. Why do you think that the diagnosis of hypercortisolism is often delayed or missed?
- Hypercortisolism presents with a wide spectrum of clinical signs and symptoms. How does this affect clinicians’ ability to diagnose this condition?
- The prevalence of hypercortisolism in certain at-risk patients is higher than previously thought. Can you discuss some of the recent data on hypercortisolism prevalence?
- Prevalence of hypercortisolism in patients with difficult-to-control diabetes was 24%.
- Prevalence of hypercortisolism in patients with difficult-to-control diabetes and difficult-to-control hypertension was 40%.
- Patients with cardiovascular disease had a higher prevalence of hypercortisolism than those without (33.3% vs 20.9%).
Advertisement
Related to this article

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.
Advertisement
Advertisement
Trending on HCPLive
1
Single Annual Injection Produces Significant and Sustained Lp(a) Reductions
2
RAPID: Etripamil Converts Two-Thirds of Recurrent PSVT Episodes After Ablation
3
Metformin May Lower Cardiac Dysfunction Risk During VEGF Inhibitor Therapy
4
Building Trust Into Community Kidney Screening, With David Van Wyck, MD
5

